2 results
Approved WMORecruiting
Core phase: The overall objective of the core phase is to investigate the efficacy, safety and tolerability of 2 dose regimens of HZN-825, a selective antagonist of lysophosphatidic acid receptor-1 (LPAR1), administered once daily (QD) or twice…
Approved WMORecruiting
The aim of the current study is two-folded. The primary aim is to assess the impact of NMP on the incidence of PNF/DGF. Secondly, we investigate the association between microcirculation and oxyhaemoglobin during NMP as measured with the MoorO2Flo…